Prognosis of non-small-cell lung cancer in patients with idiopathic pulmonary fibrosis by �씠�긽�썕
1Scientific RepoRtS |         (2019) 9:12561  | https://doi.org/10.1038/s41598-019-49026-y
www.nature.com/scientificreports
prognosis of non-small-cell lung 
cancer in patients with idiopathic 
pulmonary fibrosis
SongYi Han1,2, Yeon Joo Lee1, Jong Sun park1, Young-Jae cho  1, Ho Il Yoon1, Jae-Ho Lee1, 
choon-taek Lee1, Jin-Haeng chung3, Kyung Won Lee4 & Sang Hoon Lee5
The risk of lung cancer is higher in idiopathic pulmonary fibrosis (IPF) because both conditions 
share common risk factors. However, no standard treatment modality for LC in IPF exists due to 
rare incidence, poor prognosis, and acute exacerbation (AE) of IPF during treatment. We aimed to 
determine the efficacy of LC treatments and the prognosis in LC patients with IPF according to the LC 
stage and GAP (gender [G], age [A], and two physiology variables [P]) stage. From 2003 to 2016, 160 
retrospectively enrolled patients were classified according to the LC clinical stage and GAP stage. The 
average (±standard deviation) patient age was 70.1 ± 8.2 years; the cohort predominantly comprised 
men (94.4%). In GAP stage I, surgery was significantly associated with better survival outcomes in 
LC. In contrast, no treatment modality yielded significant clinical improvement in GAP stage II/III. 
The incidences of AE in IPF and its mortality during treatment were 13.8% and 6.3%, respectively. AE 
occurred commonly in advanced GAP stage. Active treatment should be considered in GAP stage I. The 
performance status and LC stage should be considered when deciding about the necessity of surgery for 
patients in advanced GAP stage.
Idiopathic pulmonary fibrosis (IPF) is the most frequent and severe type of idiopathic interstitial pneumonia 
(IIP) with an unknown aetiology. IPF has a median survival of approximately 2 to 3 years after diagnosis and 
presents with a histologic pattern of usual interstitial pneumonia (UIP) on computed tomography (CT)1. Disease 
progression is characterised by ongoing fibrosis, worsening dyspnoea, and decreasing pulmonary function tests 
(PFT), particularly forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO)2,3.
Emerging evidence shows that IPF is an important risk factor for lung cancer (LC) development4. Moreover, 
the prevalence of LC increases from the time of IPF diagnosis5,6. Ozawa et al. reported that the cumulative prev-
alence of LC is increased to 3.3%, 15.4%, and 54.7% after 1, 5, and 10 years from IPF diagnosis7. Previous stud-
ies showed that the prevalence of LC and IPF (LC-IPF) is higher in older men, those who smoke, and those 
with squamous cell carcinoma8,9. Although the exact relationship between LC and IPF has not yet been estab-
lished, epigenetic changes, genetic changes, and oxidative stress are thought to be involved in the development 
of LC-IPF10.
In the treatment of patients with LC-IPF, physicians are reluctant to treat LC because of the poor prognosis 
of IPF11. In addition, complications such as pneumonia, acute exacerbation of IPF (AE-IPF), acute respiratory 
distress syndrome, and air leakage after lung surgery are relatively more frequent in LC-IPF patients than in 
those with LC alone, thus resulting in higher mortality rates12,13. These complications and high mortality makes 
the treatment of LC difficult. Although some studies suggest that surgical treatment is effective in IPF patients 
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with early stage LC, little is known about the treatment, prognosis, and long-term survival of advanced stage 
patients11,14,15.
In 2012, Ley et al.16 reported the GAP index and staging system, which can be easily used to predict the mor-
tality and the timing of lung transplantation in IPF patients. Because the GAP index and stage can be obtained 
simply using gender (G), age (A), and two lung physiologic variables (P) (FVC and DLCO), clinicians can calculate 
the GAP score easily.
In this study, we aimed to investigate the effectiveness of the treatment of LC and the prognosis in patients 
with LC-IPF according to disease severity and treatment modality.
Results
Patients’ baseline characteristics. Overall, 160 patients with LC-IPF were divided into GAP stage 
I (n = 115), II (n = 36), and III (n = 9), and each GAP stage was classified into LC clinical stage I (n = 45), II 
(n = 23), III (n = 45), and IV (n = 47). Because of the few patients in GAP stage III (n = 9), GAP stage III was 
combined with GAP stage II.
Table 1 shows the comparison of the patients’ baseline characteristics according to the GAP stage. The mean 
patient age was 70.1 ± 8.2 years, and majority of the patients were men (94.4%). The median OS was 17.7 months. 
Total (n = 160) GAP I (n = 115)
GAP II/III 
(n = 45) p value
Age (year) 70.1 ± 8.2 69.6 ± 8.9 71.5 ± 6.0 0.200
Gender (male) 151 (94.4) 107 (93.0) 44 (97.8) 0.243
BMI, kg/m² 23.0 ± 3.3 23.2 ± 2.9 22.5 ± 4.0 0.191
Smoking status 0.763
  Never smoker 15 (9.4) 12 (10.4) 3 (6.7)
  Former smoker 114 (71.3) 81 (70.4) 33 (73.3)
  Current smoker 31 (19.4) 22 (19.1) 9 (20.0)
Total amount of cigarettes 
smoked in a lifetime (PYs) 37.4 ± 25.7 35.0 ± 22.5 43.8 ± 31.8 0.125
Pulmonary function test
  FVC, predicted % 85.6 ± 18.3 92.5 ± 14.6 68.0 ± 14.6 <0.001
  FEV1, predicted % 89.9 ± 19.6 96.3 ± 17.1 73.6 ± 15.8 <0.001
  DLco, predicted % 73.4 ± 20.7 79.1 ± 17.7 57.5 ± 20.5 <0.001
Histology 0.004
  Squamous cell carcinoma 76 (47.5) 52 (45.2) 24 (53.3)
  Adenocarcinoma 60 (37.5) 49 (42.6) 11 (24.4)
  Large-cell carcinoma 4 (2.5) 4 (3.5) 0
  Unclassified NSCLC 20 (12.5) 10 (8.7) 10 (22.2)
Location of lung cancer 0.550
  Right upper lobe 30 (18.7) 21 (18.3) 9 (20.0)
  Right middle lobe 6 (3.8) 5 (4.3) 1 (2.2)
  Right lower lobe 59 (36.9) 40 (34.8) 19 (42.2)
  Left upper lobe 30 (18.7) 24 (20.9) 6 (13.3)
  Left lower lobe 35 (21.9) 25 (21.7) 10 (22.2)
Clinical lung cancer stage <0.001
  I/II/III/IV 45/23/45/47 39/20/35/21 6/3/10/26
ECOG <0.001
  0/1/2/3/4 29/86/28/12/5 26/71/11/5/2 3/15/17/7/3
Primary treatment <0.001
  Conservative care 22 (13.8) 11 (9.6) 11 (24.4)
  Surgery 69 (43.1) 62 (53.9) 7 (15.6)
  Chemotherapy 58 (36.3) 35 (30.4) 23 (51.1)
  Radiotherapy 11 (6.9) 7 (6.1) 4 (8.9)
Median OS, month 17.7 22.4 6.7 <0.001
Median PFS, month 7 10.5 3.9 <0.001
Overall mortality 111 (69.4) 74 (64.3) 37 (82.2) 0.027
Table 1. Baseline characteristics according to GAP stage. Abbreviations: GAP = gender (G), age (A), and 
two physiology variables (P) (FVC and DLco) stage system; BMI = body mass index; PYs = pack-years; 
FVC = forced vital capacity; FEV1 = forced expiratory volume in one second; DLco = diffusing capacity for 
carbon monoxide; NSCLC = non-small-cell lung cancer; ECOG = Eastern Cooperative Oncology Group; 
OS = overall survival; PFS = progression-free survival. Data are presented as mean ± standard deviation, 
median, or frequency (%).
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The age, gender, body mass index, and total amount of cigarettes smoked in a lifetime among patients in GAP 
stage 1 were not significantly different from those in GAP stages II and III. Patients with high Eastern Cooperative 
Oncology Group (ECOG) score and advanced LC were significantly more distributed in the higher GAP stages 
than in the GAP stage I (p < 0.001 and p < 0.001, respectively). Moreover, lung function, median overall sur-
vival (OS), and median progression-free survival (PFS) were lower in high GAP stage than in low GAP stage 
(p < 0.001, p < 0.001, and p < 0.001, respectively). In terms of histologic type, the distribution of squamous cell 
carcinoma and adenocarcinoma was similar in GAP stage I.
Patients’ baseline characteristics according to treatment modality. The 115 patients with GAP 
stage I were divided according to the treatment modality. Table 2 shows the baseline characteristics. Of these 
patients, the mean age was the highest in among patients who received conservative care (77.8 ± 6.1, p = 0.006); 
the number of patients with advanced LC stage and those with poor performance status (PS) were significantly 
higher among those who received chemotherapy and radiotherapy (p < 0.001 and p < 0.001, respectively). 
Patients with GAP stage I who underwent surgery showed a significantly longer median PFS and OS than those 
who received other treatment modalities.
The age, gender, total amount of cigarettes smoked, and PFT result according to treatment modality were not 
significantly different between GAP stage II and III (Table 3). Similar to those with GAP stage I, the number of 
patients with early LC was higher in the surgery group than in the other treatment groups. Among the treatment 
modalities, OS and PFS were the longest in surgery, but the OS was considerably lower for of patients with GAP 
stages II and III than for those with GAP stage I.
Survival analysis. In the survival analysis of all patients, smoking status, ECOG PS, GAP stage, primary 
treatment modality, and LC clinical stage were adjusted for using Cox proportional hazard regression model. 
Age, gender, and PFT were not included in the Cox proportional hazards model because they are variables of the 
GAP staging system. Table 4 shows the survival analysis according to the GAP stage. In GAP stage I, the most 
significant increase in survival probability was in the surgery group (Fig. 1a; hazard ratio [HR] = 0.233; 95% con-
fidence interval [CI]: 0.094–0.574; p = 0.005). However, unlike GAP stage I, no survival benefit was found in the 
surgery group as in the GAP stages II and III (Fig. 1b; p = 0.377). Advanced LC stage and higher ECOG PS were 
substantially associated with poor outcome. Smoking status was a significant prognostic factor in GAP stages II 
and III (p = 0.031).
Conservative 
care (n = 11)
Operation 
(n = 62)
Chemotherapy 
(n = 35)
Radiotherapy 
(n = 7) P value
Age 77.8 ± 6.1 69.4 ± 8.4 67.2 ± 9.5 70.3 ± 7.9 0.006
Gender (male) 9 (81.8) 60 (96.8) 32 (91.4) 6 (85.7) 0.289
BMI, kg/m² 22.6 ± 2.6 23.6 ± 3.1 22.9 ± 2.8 22.2 ± 2.1 0.433
Smoking status 0.135
  Never smoker 0 8 (12.9) 4 (11.4) 0
  Former smoker 8 (72.7) 47 (75.8) 22 (62.9) 4 (57.1)
  Current smoker 3 (27.3) 7 (11.3) 9 (25.7) 3 (42.9)
Total amount of cigarettes smoked 
in a lifetime (PYs) 50.9 ± 20.8 32.1 ± 21.3 35.1 ± 24.9 34.3 ± 15.7 0.095
Pulmonary function test
  FVC, predicted % 98.6 ± 15.7 95.2 ± 13.5 86.9 ± 14.5 86.9 ± 15.6 0.068
  FEV1, predicted % 106.6 ± 14.5 97.2 ± 16.7 93.2 ± 17.6 87.3 ± 16.6 0.078
  DLCO, predicted % 75.2 ± 18.8 81.7 ± 16.3 78.4 ± 19.6 65.4 ± 14.0 0.109
Histologic type 0.009
  Squamous cell carcinoma 6 (54.5) 30 (48.4) 13 (37.1) 3 (42.9)
  Adenocarcinoma 4 (36.4) 28 (45.2) 16 (45.7) 1 (14.3)
  Large cell carcinoma 0 4 (6.5) 0 0
  Unclassified NSCLC 1 (9.1) 0 (0) 6 (17.1) 2 (42.9)
Clinical stage <0.001
  I/II/III/IV 4/2/4/1 33/17/11/1 0/0/18/17 2/1/2/2
ECOG <0.001
0/1/2/3/4 1/7/2/0/1 22/37/3/0/0 3/25/5/2/0 0/2/1/3/1
Median OS, month 13.4 ± 9.4 42.0 ± 37.5 11.2 ± 18.4 11.9 ± 7.8 <0.001
Median PFS, month 3.9 ± 4.0 34.6 ± 39.0 7.5 ± 18.3 8.2 ± 6.1 <0.001
Table 2. Comparison of characteristics according to treatment modality in GAP stage I. Abbreviations: 
GAP = gender (G), age (A), and two physiology variables (P) (FVC and DLco)) stage system; BMI = body 
mass index; PYs = pack-years; FVC = forced vital capacity; FEV1 = forced expiratory volume in one 
second; DLco = diffusing capacity of the lung for carbon monoxide; NSCLC = non-small-cell lung cancer; 
ECOG = Eastern Cooperative Oncology Group; OS = overall survival; PFS = progression-free survival. Data are 
presented as mean ± standard deviation, median, or frequency (%).
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Each GAP stage was also divided into early LC and advanced LC (Fig. 2 and Supplementary Table S1). In 
both early and advanced LC stages with GAP stage I, survival was significantly increased in the surgery group 
(p = 0.020 in GAP stage I and p = 0.020 in GAP stage II/III). In GAP stages II and III, any treatment modalities 
Conservative 
care (n = 11)
Operation 
(n = 7)
Chemotherapy 
(n = 23)
Radiotherapy 
(n = 4) P value
Age (years) 73.1 ± 7.2 71.4 ± 7.3 71.0 ± 5.4 70.3 ± 5.5 0.925
Gender (male) 10 (90.9) 7 (100.0) 23 (100.0) 4 (100.0) 0.409
BMI, kg/m² 22.6 ± 4.7 25.7 ± 3.8 21.4 ± 3.5 22.9 ± 3.8 0.132
Smoking status 0.083
  Never smoker 0 0 3 (13.0) 0
  Former smoker 10 (90.9) 7 (100.0) 14 (60.9) 2 (50.0)
  Current smoker 1 (9.1) 0 6 (26.1) 2 (50.0)
Total amount of cigarettes smoked 
in a lifetime (PYs) 40.1 ± 20.4 36.4 ± 21.4 39.1 ± 27.1 93.8 ± 58.5 0.087
Pulmonary function test
  FVC, predicted % 70.7 ± 16.0 72.9 ± 5.3 64.3 ± 16.2 72.8 ± 8.5 0.436
  FEV1, predicted % 75.6 ± 19.7 78.6 ± 5.2 70.0 ± 16.5 79.3 ± 10.1 0.496
  DLCO, predicted % 56.5 ± 17.9 67.7 ± 25.1 55.6 ± 20.3 51.7 ± 18.6 0.610
Histologic type 0.113
  Squamous cell carcinoma 8 (72.7) 6 (85.7) 9 (39.1) 1 (25.0)
  Adenocarcinoma 2 (18.2) 1 (14.3) 7 (30.4) 1 (25.0)
  Unclassified NSCLC 1 (9.1) 0 7 (30.4) 2 (50.0)
Clinical stage <0.001
  I/II/III/IV 1/1/1/8 4/2/0/1 0/0/9/14 1/0/0/3
ECOG 0.260
0/1/2/3/4 0/3/4/2/2 0/4/3/0/0 3/7/9/4/0 0/1/1/1/1
Median OS, month 4.5 24.5 6.9 9.0 0.011
Median PFS, month 1.8 12.5 3.6 5.0 0.003
Table 3. Comparison of characteristics according to treatment modality in GAP stage II and III. Abbreviations: 
GAP = gender (G), age (A), and two physiology variables (P) (FVC and DLco)) stage system; BMI = body 
mass index; PYs = pack-years; FVC = forced vital capacity; FEV1 = forced expiratory volume in one 
second; DLco = diffusing capacity of the lung for carbon monoxide; NSCLC = non-small-cell lung cancer; 
ECOG = Eastern Cooperative Oncology Group; OS = overall survival; PFS = progression-free survival. Data are 
presented as mean ± standard deviation, median, or frequency (%).
Variables
GAP stage I GAP stage II/III
HR 95% CI P value HR 95% CI P value
Lung cancer stage 0.001 0.002
  Stage I 1.000 1.000
  Stage II 1.489 0.722–3.072 0.281 0.183 0.023–1.455 0.108
  Stage III 1.508 0.715–3.179 0.281 5.384 0.520–55.729 0.158
  Stage IV 7.775 2.593–23.307 <0.001 35.94 3.606–358.215 0.002
ECOG 0.077 0.007
  ECOG 0 and 1 1.000 1.000
  ECOG 2 1.134 0.471–2.732 0.779 3.71 1.436–9.587 0.007
  ECOG 3 and 4 3.037 1.152–8.010 0.025 4.711 1.558–14.240 0.006
Primary treatment 0.005 0.377
  Conservative care 1.000 1.000
  Operation 0.233 0.094–0.574 0.002 2.118 0.261–17.207 0.482
  Chemotherapy 0.613 0.210–1.787 0.370 0.818 0.296–2.265 0.700
  Radiotherapy 0.421 0.115–1.541 0.191 0.323 0.077–0.077 0.123
Total amount of cigarettes 
smoked in a lifetime (PYs) 0.993 0.982–1.004 0.189 1.016 1.002–1.031 0.031
Table 4. Cox multivariate proportional hazard analysis according to GAP stage. Abbreviations: HR = Hazard 
ratio, GAP = gender (G), age (A), and two physiology variables (P) (FVC and DLco)) stage system; PYs = pack-
years; ECOG = Eastern Cooperative Oncology Group. *Adjusted for lung cancer clinical stage, ECOG, primary 
treatment, and smoking amount.
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failed to considerably improve survival in early or advanced LC stages. ECOG PS was significantly correlated with 
mortality in advanced LC.
Classification according to the GAP stage and treatment modality. Of the 160 patients, 22, 69, 58, 
and 11 received conservative therapy, surgery, chemotherapy, and radiation therapy as primary treatment, respec-
tively. AE-IPF occurred in 1 (4.5%), 10 (14.5%), 7 (12.1%), and 4 (36.4%) patients who received conservative ther-
apy, surgery, chemotherapy, and radiotherapy, respectively (Table 5). The toxicity of all AE was higher than grade 
4. AE-IPF was significantly more frequent in GAP stage II/III than in GAP stage I in patients who received both 
surgery and chemotherapy (p = 0.050 and p = 0.007, respectively). In particular, in patients who received chemo-
therapy, mortality owing to AE was also significantly higher in GAP stage II/III than in GAP stage I (p = 0.002). 
Most complications such as prolonged air leakage, subcutaneous emphysema, cytopenia, or pneumonia other 
than AE were lower than grade 3 and did not differ according to the GAP stages.
Discussion
The standard treatment modality for LC-IPF is yet to be established because of the short median OS due to IPF, 
the high complication rate occurring after anti-cancer treatment such as AE-IPF, and the rarity of comorbidity 
of IPF and LC17,18. In this study, we investigated the efficiency of treatment and prognosis of LC-IPF according 
to treatment modalities considering the severity of LC and IPF, ECOG PS, and smoking status, while previous 
studies primarily focused on the treatment of LC stage. Our study showed that surgery was an effective treatment 
modality for GAP stage I patients with LC, while other treatment modalities of LC failed to show effectiveness 
regardless of the GAP stage.
In 2015, Tomassetti et al.15 described that LC developing in IPF significantly decreased the median OS com-
pared with IPF without LC (LC-IPF: 38.7 months, IPF without LC: 63.9 months; HR = 5.0; 95% CI: 21.91–8.57; 
p < 0.001). Saito et al.19 reported the survival rates after pulmonary resection of 350 patients with pathologic stage 
IA and found that the 5-year survival rate was significantly reduced in patients with IPF (54.2% in LC-IPF and 
88.3% in LC only, p < 0.001), and IPF was the only prognostic factor (p = 0.04). These studies showed that com-
pared with LC alone or IPF alone, LC-IPF is related with poor prognosis. In our study, the prognosis of LC-IPF 
was also poor; the median OS and PFS were 17.7 and 7.0 months, respectively. Additionally, as the GAP stage 
increased, the survival of patients with LC-IPF rapidly reduced in all treatment groups compared with that in 
GAP stage I. This could explain why there is no effective treatment modality in higher GAP stages. It is possible 
that low efficacy of LC treatments because of poor survival is likely to be more affected by the progression and 
severity of IPF itself than by LC severity. Watanabe et al. reported that surgery for LC can be helpful in selective 
patients with LC-IPF. In their study, although the hospital mortality (7.1% vs 1.9%, p = 0.03) or AE (7.1% vs 0.0%, 
p < 0.001) rate after lung surgery was significantly higher in patients with LC-IPF than in LC only patients, the 
5-year survival rate for stage I LC with IPF was 61.6% compared with 83.0% in patients without IPF. Although 
some studies reported that the history of AE, surgical procedure, male sex, elevated LDH/KL-6, preoperative ster-
oid use, and low FVC are risk factors for mortality or AE of interstitial pneumonia, these studies were performed 
with relatively small numbers of patients than those in our study and did not suggest a clear selection criteria 
of patients for whom surgery could be beneficial12,20–22. In the current study, surgery was an effective treatment 
modality in LC patients with GAP stage I. This finding indicates that the assessment of IPF according to the GAP 
stage could be helpful in identifying patients who would benefit from surgery. Furthermore, our study showed 
Figure 1. Comparison of survival probability according to treatment modality in GAP stage I (a) and GAP 
((gender [G], age [A]), and two physiology variables (P) (FVC and DLCO)) stage system) stage II and III (b). Cox 
regression models were adjusted for lung cancer clinical stages, Eastern Cooperative Oncology Group (ECOG), 
primary treatment, and total amount of cigarettes smoked in a lifetime.
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that advanced LC stage and poor PS were significantly related with poor outcomes. However, the high frequency 
of AE and AE-related mortality associated with anticancer therapy is an important issue for determining the need 
for surgery even at low LC stages. The incidence rate of AE ranges from 7.1% to 33.0% in surgery14,23,24. In the 
present study, the incidence of AE was 14.5% in the surgery group. Moreover, the incidence of AE was signifi-
cantly higher in patients with advanced GAP stage. As such, efforts are being made to prevent the development of 
AE. A recent study reported that perioperative pirfenidone significantly decreased the incidence of AE compared 
with control, although this was a retrospective study and included only a small number of patients25. Therefore, 
physicians should be cautious regarding the occurrence of AE when performing surgery in LC patients with 
advanced GAP stage and should consider the use of pirfenidone during the perioperative period.
The clinical value of chemotherapy and radiotherapy has been studied in patients with inoperable condi-
tions; however, their role remains unclear owing to the significantly lower OS and higher complication rates than 
those for surgery. Chen et al. performed a meta-analysis to investigate the efficacy and safety of chemotherapy in 
patients with non-small-cell LC (NSCLC) and interstitial lung disease (ILD)26. In their study, although chemo-
therapy was associated with a higher incidence of AE, high overall response rate (ORR) and disease control rate 
(DCR) were achieved (41.3% and 77.7%, respectively), and the 1-year survival rate was approximately 29.4%. 
Watanabe et al.27 reported the efficacy of chemotherapy in 23 patients with LC-IPF. In their study, the ORR, DCR, 
and 1-year survival rate were 42.9%, 81.0%, and 28.6%. As such, they concluded that chemotherapy might be 
effective in NSCLC patients with ILD or IPF. However, these studies reached their conclusions either indirectly 
through comparison with other studies or by conducting a study with only a small number of patients. In con-
trast, Kanaji et al.28 reported a median PFS and median OS after chemotherapy that were significantly shorter 
in LC-IPF patients than in LC patients without ILD. In their study, DCR was also significantly lower in patients 
with LC-IPF than in those with NSCLC alone (87% for non-ILD and 53% for IPF, p < 0.001). Furthermore, some 
studies reported incidence rates of AE ranging from 5.6% to 30% with chemotherapy29,30. Kato et al. showed that 
pemetrexed-related pulmonary toxicity developed in 12.0% of patients with IIP and in 1.1% of patients without 
IIP, with a significantly higher proportion of patients with IIP (odds ratio: 11.8; p = 0.03)31. According to a study 
by Kenmotsu et al.30, patients with a UIP pattern had a significantly higher incidence of chemotherapy-associated 
AE at 30% than patients with a non-UIP pattern at 8% (p = 0.005). Furthermore, AE of grade 3 or higher occurred 
in a higher proportion of patients with UIP pattern (p = 0.003). In our study, although it was not significant, 
chemotherapy tended to decrease the risk of mortality. Additionally, AE was significantly more frequent in 
Figure 2. Subgroup analysis for survival according to the primary treatment after classifying the patient as 
GAP ((gender [G], age [A]), and two physiology variables (P) (FVC and DLCO)) stage system) stage and the lung 
cancer (LC) stage. (a) GAP stage I and LC stages I and II, (b) GAP stage I and LC stage III and IV, (c) GAP stage 
II and III and LC stage I and II, and (d) GAP stages II and III and LC stage III and IV. In GAP stage I, surgery 
significantly improved the survival in both early and advanced LC stages (p = 0.023 and p = 0.019). In GAP 
stages II and III, any treatment modalities failed to significantly improve survival in early or advanced LC stages.
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patients with advanced GAP stage in the chemotherapy group (p = 0.007). Therefore, when deciding the applica-
bility of chemotherapy in inoperable cases, the GAP stage might be a helpful criterion. Targeted therapy for LC 
has recently been introduced, and immune therapy has also attracted attention. Further large studies are needed 
to investigate the efficacy or safety of chemotherapy in LC-IPF.
Few studies on the effect of radiotherapy in LC-IPF have been conducted. Although radiotherapy is as effective 
as surgery in patients with early LC without IPF, it yields poor outcomes in LC-IPF32–34. Some researchers spec-
ulate that the incidence of acute respiratory deterioration will increase in radiotherapy; however, little research 
has been conducted to support this theory. In a study of curative radiotherapy in 7 patients with IPF, 2 patients 
showed partial remission and 5 patients did not achieve such change. Moreover, acute respiratory deteriora-
tion occurred in 5 patients14. According to Bahig et al.34, of the 150 patients with stage I NSCLC in their study, 
5 patients had features of IPF, of which three developed grade 5 pneumonitis. Collectively, the above studies 
indicate that patients with LC-IPF have a higher risk of severe toxicity. Similar to previous studies, 4 of the 11 
patients experienced AE, and the incidence of AE tended to increase as the GAP stage advanced in our study. This 
result suggested that radiotherapy had limited therapeutic benefit in LC-IPF, and the applicability of radiotherapy 
should be decided by a multidisciplinary team of pulmonologist, radiologist, clinical oncologist, and radiation 
oncologist.
There are several limitations in this study. First, in the present study, IPF diagnosis was performed by chest CT 
without tissue analysis in a relatively large number of patients (n = 130, 81.2%). However, as highlighted in the 
2018 Guidelines for accurate diagnosis, the multidisciplinary approach, including pulmonologists, chest specific 
radiologists, and a pulmonary pathologist, increased the accuracy of the diagnosis. Second, the conservative care 
group might have individual characteristics that may make them ineligible for anticancer therapies. However, 
the ECOG PS and clinical stage of LC in the conservative care group were not worse than those in other treat-
ment groups, and the GAP stage and smoking amount were considered in this study. The comorbidity was also 
not different from other treatment groups (data not shown). Third, there were only few GAP stage III patients. 
When calculating the GAP stage, patients who failed to perform DLCO owing to respiratory insufficiency might 
have been given a point in the “DLCO cannot perform” category, and we could not verify the data of those patients 
due to the retrospective study design. There is need for further studies on GAP stage III patients. Finally, because 
radiotherapy tends to be performed selectively in inoperable cases, only a small number of patients received 
radiotherapy as primary treatment.
In conclusion, active therapies such as surgery in LC-IPF patients with GAP stage I are recommended. 
However, at the advanced GAP stage, no beneficial treatment modalities were found. Therefore, physicians should 
carefully evaluate the patient’s condition, and the applicability of surgery in patients with advanced LC and higher 
GAP stages should be decided by a multidisciplinary team.
GAP stage I 
(n = 115)
GAP stage II/III 
(n = 45) p value
Operation (n = 69) (GAP stage I (n = 62), GAP stage II/III (n = 7)
  Prolonged air leak 9 (14.5) — 0.150
  Subcutaneous emphysema 4 (6.5) — 0.347
  Pneumonia 1 (1.6) 2 (28.6) 0.014
  Pneumothorax 6 (9.7) 2 (28.6) 0.191
  AE-IPF 7 (11.3) 3 (42.9) 0.050
  Others 3 (4.9) — 0.414
Chemotherapy (n = 58) (GAP stage I (n = 35), GAP stage II/III (n = 23)
  Cytopenia 3 (8.6) 2 (8.7) 0.987
  GI trouble 3 (8.6) 1 (4.3) 0.523
  Skin eruption 1 (2.9) 1 (4.3) 0.763
  Pneumonia 1 (2.9) 1 (4.3) 0.763
  Septic shock — 1 (4.3) 0.175
  Pneumonitis 2 (6.9) — 0.142
  AE-IPF 1 (2.9) 6 (26.1) 0.007
Radiotherapy (n = 11) (GAP stage I (n = 7), GAP stage II/III (n = 4)
  Pneumonia 1 (14.3) — 0.227
  AE-IPF 2 (28.6) 2 (50.0) 0.480
Table 5. Complications that occurred after treatment classified according to GAP stage and treatment modality. 
Abbreviations: GAP = gender (G), age (A), and two physiology variables (P) (FVC and DLco)) stage system; 
GI = gastro-intestinal, AE-IPF = acute exacerbation of idiopathic pulmonary fibrosis. The AE-IPF was defined 
within one month after surgical resection in surgery, while it was defined as the onset of AE-IPF within one 
month after one cycle in chemotherapy and radiotherapy. Other complications in surgery included one case 
each of acute thrombosis, post-operation atrial fibrillation, and post-operation atelectasis. Note: Values in 
parentheses are percentages.
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Methods
Study population. The study was conducted retrospectively in Seoul National University Bundang Hospital, 
from 1 November 2003 to 31 August 2016. Initially, 287 patients with LC-IPF were enrolled, and IPF was diag-
nosed and confirmed by a multidisciplinary team consisting of pulmonologists, a chest specific radiologist, and 
a pulmonary pathologist in accordance with the 2011 diagnostic criteria set by the International Consensus 
Statement of the American Thoracic Society and European Respiratory Society1. Only patients with biopsy-con-
firmed LC were included. Of the 287 patients, 127 were excluded due to malignancy other than LC (n = 9), IIP 
other than IPF (n = 8), incomplete data such as no PFT results or non-biopsy proven LC (n = 75), small-cell 
LC (n = 29), and transfer to other hospital without treatment (n = 6). Finally, 160 patients with LC-IPF were 
examined. GAP stage I comprised the most patients (n = 115), followed by GAP stage II and III at 35 and 9, 
respectively. The patient enrolment flow chart is shown in Fig. 3. The Institutional Review board and Ethics 
Committee of Seoul National University Bundang Hospital approved the study (IRB number: B-1707/411-402). 
Written informed consent was waived owing to the retrospective nature of the study. All methods were performed 
in accordance with the Declaration of Helsinki.
Data collection and statistical analysis. The age, gender, smoking history, comorbidity, ECOG PS at 
treatment initiation, and time of LC diagnosis and recurrence were investigated in this study using data from the 
patient’s medical records. The PFT results were used within one month of LC diagnosis. All data represented as 
mean ± S.D. unless otherwise stated. High-resolution CT, positron emission tomography, brain magnetic reso-
nance imaging, and bronchoscopy confirmed the location, clinical stage, and fibrotic area involvement of LC. LC 
was pathologically confirmed via bronchoscopic biopsy, percutaneous needle aspiration, or surgical lung biopsy. 
Early LC was defined as stage I or II, while advanced LC was defined as stage III or IV. The GAP score was cal-
culated using gender (0–2 points), FVC (4–5 points), and DLCO (0–3 points), and classified into stages I (0–3 
points), II (4–5 points), or III (6–8 points)16. AE-IPF was defined as that occurring within 4 weeks after surgical 
resection and within 4 weeks after the first cycle of chemotherapy or radiotherapy17,18. PFS was calculated from 
the beginning of the treatment to the development of recurrence, whereas OS was calculated starting from the 
diagnosis of LC-IPF to the date of death or last follow-up.
Statistical analysis. Categorical variables were analysed using Chi-squared distribution or Fisher’s exact 
test, and continuous variables were analysed using the Student t-test or Mann-Whitney U test. Cox proportional 
hazard regression analysis and Firth logistic regression were used to identify the risk factors of survival of LC-IPF 
patients. Survival time was calculated starting from the date of LC diagnosis to the date of death or last follow-up. 
Survival was investigated using data from the Ministry of Public Administration and Security and medical charts 
between 2003 and 2017. All statistical analyses were performed using IBM SPSS Statistics (version 22.0). An 
adjusted p-value of < 0.05 was considered significant in this study.
Data Availability
The datasets generated during the current study are available from the corresponding author on request.
Figure 3. Patient recruitment flow chart. Abbreviation: LC-IPF = lung cancer with idiopathic pulmonary 
fibrosis; ILD = interstitial lung disease; ECOG = Eastern Cooperative Oncology Group; GAP = gender (G), age 
(A), and two physiology variables (P) (FVC and DLCO) stage system.
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